Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on October 25, 2023. The filing addresses Item 5.02 regarding the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation arrangements.
- Compensation Rate: Approximately $375.00 per hour for services rendered by the Acting CFO.
- Payment Recipient: WhiteCap Search Holdings, LLC (per engagement agreement dated February 3, 2023).
Material Changes
Executive Appointment: On October 25, 2023, the Board appointed Marshall H. Woodworth as Acting Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective October 27, 2023.
Background: Mr. Woodworth previously served as CFO for Nevakar Inc., Braeburn Pharmaceuticals Inc., Aerocrine AB, and Furiex Pharmaceuticals, Inc.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks. It confirms that Mr. Woodworth has no family relationships with directors or officers and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Woodworth's appointment (October 27, 2023).
- Confirm the hourly compensation rate of $375.00 paid to WhiteCap Search Holdings, LLC.
- Review the engagement agreement dated February 3, 2023, for additional terms.
- Note that this filing does not contain financial performance data for the period.